Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Quality Assurance Programs topic
No spam. Unsubscribe anytime.
Board withdraws QA rulemaking for §1711 to reassess after AB 1286 changes, delegates drafting to members
Summary
The board voted to withdraw an existing rulemaking package to amend CCR §1711 (quality assurance programs) and to direct staff and designated board members to develop updated regulatory language for committee review, citing AB 1286 and upcoming mandatory medication error reporting.
The California State Board of Pharmacy voted to withdraw the current rulemaking file proposing changes to California Code of Regulations, Title 16, §1711 (quality assurance programs) and to direct further development of the proposal before resubmitting it to the committee process.
Board staff explained that although the board approved proposed language in February 2023, formal rulemaking was delayed until August 2024. Since that time, Assembly Bill 1286 and its mandatory medication error reporting provisions have advanced and take effect September 1, 2025. Given the changed statutory landscape and the board's one‑year deadline for completing rulemaking steps, staff recommended withdrawing the current file to allow the board to reexamine the language with the new statutory context in mind.
Following committee discussion, President Seung Oh and staff recommended that the board withdraw the rulemaking and delegate development of revised language to committee members Maria Serpa and KK John (with staff support) for initial drafting and then referral to the Enforcement and Compounding Committee. The motion to withdraw and delegate passed on roll call. Members said the goal is to ensure proposed regulatory language addresses system‑level QA and “just culture” concepts rather than narrowly prescriptive, individual‑error approaches.
Why it matters: AB 1286 changes mandatory medication error reporting and related requirements; the board said it wants to ensure any QA regulation is consistent with the new statutory framework and the board’s patient safety objectives.
What’s next: Maria Serpa and KK John, working with staff and counsel, will draft revised language and return it to the Enforcement and Compounding Committee for further public discussion and a future board vote.
